QurCan Therapeutics and Lilly Advance Nucleic Acid Therapies
Cambridge, Massachusetts, September 15, 2026 QurCan Therapeutics has entered into a strategic research and collaboration agreement with Eli Lilly...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Cambridge, Massachusetts, September 15, 2026 QurCan Therapeutics has entered into a strategic research and collaboration agreement with Eli Lilly...
THE WOODLANDS, Texas, August 12, 2026 Autonomix Medical, Inc. announced the successful completion of a Good Laboratory Practice (GLP)...
THE WOODLANDS, Texas, July 23, 2026 Autonomix Medical, Inc. announced that it has been granted U.S. Patent No. 12,471,776,...
